Citations

Mayo Clinic

Showing 10 of 108551 citations.

Soft Pink Plaques at the Site of Breast Cancer Vaccination: Answer
Wang, Katherine , Hall, Matthew R., Chumsri, Saranya , Wang, Katherine L , Sokumbi, Olayemi

The American Journal of Dermatopathology | April 18, 2024 | Volume: 46 | Issue: 5 | Pages: 320-321

10.1097/dad.0000000000002683 | PMID 40008799 Get It

Mapping Proximity to Infectious Disease Physicians Across the United States
Maamari, Julian , Chen, Zhuo , Motairek, Issam , Al‐Kindi, Sadeer , Fleisher, Jorge , Maamari, Julian

Open Forum Infectious Diseases | April 18, 2024 | Volume: 11 | Issue: 5 | Pages: No page available

10.1093/ofid/ofae208 | PMID 38737425 Get It

Abstract Enduring shortages of infectious disease physicians across the United States continue despite efforts to mitigate the problem. The recent fellowship match results underscore the difficulty in rectifying that shortage. Our report sheds light on the current geographic distribution of US infectious disease physicians and highlights the challenges faced by rural communities.
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Jacobson, Caron A. , Ghobadi, Armin , Ahmed, Sairah , Miklos, David B. , Perales, Miguel‐Angel , Fingrut, Warren , Pennisi, Martina , Gowda, Lohith , Abid, Muhammad Bilal , Hong, Sanghee , Kharfan‐Dabaja, Mohamed A. , Khurana, Arushi , Badar, Talha , Hu, Zhen‐Huan , Wang, Hailin , Baer, Anjani, Baro, Elande , Miao, Harry , Spooner, Clare, Xu, Hairong, Pasquini, Marcelo C. , Ghobadi, Armin , Ahmed, Sairah , Miklos, David B , Perales, Miguel-Angel , Fingrut, Warren B , Shadman, Mazyar , Majhail, Navneet S , Kharfan-Dabaja, Mohamed A , Badar, Talha , Bennani, N Nora , Herr, Megan M. , Pasquini, Marcelo , Abid, Muhammad Bilal , Locke, Frederick L. , Siddiqi, Tanya , Muñoz, Javier , Gauthier, Jordan , Shadman, Mazyar , Mirza, Abu‐Sayeef , Majhail, Navneet S. , Lin, Yi , Bennani, N. Nora

Blood | April 18, 2024 | Volume: 143 | Issue: 26 | Pages: 2722-2734

10.1182/blood.2023023447 | PMID 38635762 Get It

Abstract Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world setting, 1290 patients who received axi-cel between 2017 and 2020 were identified from the Center for International Blood and Marrow Transplant Research database; 106 and 169 patients were included from the ZUMA-1 and ZUMA-7 trials, respectively. Overall survival was consistent across race/ethnicity groups. However, non-Hispanic (NH) Black patients had lower overall response rate (OR, 0.37; 95% CI, 0.22-0.63) and lower complete response rate (OR, 0.57; 95% CI, 0.33-0.97) than NH White patients. NH Black patients also had a shorter progression-free survival vs NH White (HR, 1.41; 95% CI, 1.04-1.90) and NH Asian patients (HR, 1.67; 95% CI, 1.08-2.59). NH Asian patients had a longer duration of response than NH White (HR, 0.56; 95% CI, 0.33-0.94) and Hispanic patients (HR, 0.54; 95% CI, 0.30-0.97). There was no difference in cytokine release syndrome by race/ethnicity; however, higher rates of any-grade immune effector cell–associated neurotoxicity syndrome were observed in NH White patients than in other patients. These results provide important context when treating patients with R/R LBCL with CAR T-cell therapy across different racial and ethnic groups. ZUMA-1 and ZUMA-7 (ClinicalTrials.gov identifiers: #NCT02348216 and #NCT03391466, respectively) are registered on ClinicalTrials.gov.
Executive Summary: State-of-the-Art Review: Fostering Collaborative Teamwork—A Comprehensive Approach to Vascular Graft Infection Following Arterial Reconstructive Surgery
Tabaja, Hussam , Chesdachai, Supavit , Shah, Aditya , Wilson, Walter R., Shah, Aditya S , Erben, Young M, Chesdachai, Supavit , Tabaja, Hussam , Stevens, Ryan W. , DeMartino, Randall R. , Erben, Young , Baddour, Larry M. , DeSimone, Daniel C.

Clinical Infectious Diseases | April 18, 2024 | Volume: 78 | Issue: 6 | Pages: 1391-1392

10.1093/cid/ciae153 | PMID 38635420 Get It

Abstract Vascular graft infection (VGI) is one of the most serious complications following arterial reconstructive surgery. VGI has received increasing attention over the past decade, but many questions remain regarding its diagnosis and management. In this review, we describe our approach to VGI through multidisciplinary collaboration and discuss decision-making for challenging presentations. This document will concentrate on VGI that impacts both aneurysms and pseudoaneurysms excluding the ascending thoracic aorta.
Invited Commentary: The Double-edged Sword of Bias in Medical Imaging Artificial Intelligence
Rouzrokh, Pouria , Erickson, Bradley J. , Erickson, Bradley J , Rouzrokh, Pouria

RadioGraphics | April 18, 2024 | Volume: 44 | Issue: 5 | Pages: No page available

10.1148/rg.230243 | PMID 38635455 Get It

Passive immunotherapies for the next influenza pandemic
Focosi, Daniele , Senefeld, Jonathon W. , Joyner, Michael J. , Sullivan, David , Senefeld, Jonathon W , Sullivan, David J , Joyner, Michael J , Focosi, Daniele , Franchini, Massimo , Pekosz, Andrew , Maggi, Fabrizio , Casadevall, Arturo

Reviews in Medical Virology | April 18, 2024 | Volume: 34 | Issue: 3 | Pages: No page available

10.1002/rmv.2533 | PMID 38635404 Get It

AbstractInfluenzavirus is among the most relevant candidates for a next pandemic. We review here the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly reviewing the other existing antiviral options, we discuss in detail the evidences supporting the efficacy of passive immunotherapies against influenzavirus, with a focus on convalescent plasma.
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Konstantinopoulos, Panagiotis A. , Cheng, Su–Chun, Lee, Elizabeth K. , Costa, Alexandre André Balieiro Anastácio da , Gulhan, D. , Hendrickson, Andrea E. Wahner , Kochupurakkal, Bose , Kolin, David L. , Kohn, Elise C. , Liu, Joyce F. , Penson, Richard T. , Stover, Elizabeth H. , Curtis, Jennifer, Sawyer, Hannah , Polak, Madeline , D’Andrea, Alan D. , Matulonis, Ursula A. , da Costa, Alexandre André B A , Gulhan, Doga , Wahner Hendrickson, Andrea E , D'Andrea, Alan , Shapiro, Geoffrey I , Matulonis, Ursula A , Konstantinopoulos, Panagiotis A , Chowdhury, Dipanjan , Färkkilä, Anniina , Shapiro, Geoffrey I.

JCO Precision Oncology | April 18, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.23.00635 | PMID 38635934 Get It

PURPOSE The multicenter, open-label, randomized phase 2 NCI-9944 study ( NCT02595892 ) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank P = .044, which met the one-sided significance level of 0.1 used for sample size calculation). METHODS We report here the final overall survival (OS) analysis and biomarker correlations (ATM expression by immunohistochemistry, mutational signature 3 and a genomic biomarker of replication stress) along with post-hoc exploratory analyses to adjust for crossover from gemcitabine to gemcitabine/berzosertib. RESULTS At the data cutoff of January 27, 2023 (>30 months of additional follow-up from the primary analysis), median OS was 59.4 weeks with gemcitabine/berzosertib versus 43.0 weeks with gemcitabine alone (HR 0.79, 90% CI 0.52 to 1.2, one-sided log-rank P = .18). An OS benefit with addition of berzosertib to gemcitabine was suggested in patients stratified into the platinum-free interval ≤3 months (N = 26) subgroup (HR, 0.48, 90% CI 0.22 to 1.01, one-sided log-rank P =.04) and in patients with ATM-negative/low (N = 24) tumors (HR, 0.50, 90% CI 0.23 to 1.08, one-sided log-rank P = .06). CONCLUSION The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.
Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein (CAMKV) Autoimmune Encephalitis
Gilligan, Michael , Lesnick, Connie , Guo, Yong , Nowak, Mihaela, Shah, Maulik , Wittenborn, J. R., Basal, Eati, Hinson, Shannon R., Yang, Binxia , Dubey, Divyanshu , Mills, John R. , Pittock, Sean J. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Pittock, S J , Lesnick, Connie E, Bradshaw, Michael , Hinson, Shannon, Dubey, Divyanshu , Zekeridou, Anastasia , McKeon, Andrew , Dubey, Divyanshu , Gilligan, Michael , Ladha, Shafeeq , Wittenborn, John R., Yang, Binxia , McKeon, Andrew

Annals of Neurology | April 18, 2024 | Volume: 96 | Issue: 1 | Pages: 21-33

10.1002/ana.26943 | PMID 38634529 Get It

ObjectivesTo report an autoimmune paraneoplastic encephalitis characterized by immunoglobulin G (IgG) antibody targeting synaptic protein calmodulin kinase‐like vesicle‐associated (CAMKV).MethodsSerum and cerebrospinal fluid (CSF) samples harboring unclassified antibodies on murine brain‐based indirect immunofluorescence assay (IFA) were screened by human protein microarray. In 5 patients with identical cerebral IFA staining, CAMKV was identified as top‐ranking candidate antigen. Western blots, confocal microscopy, immune‐absorption, and mass spectrometry were performed to substantiate CAMKV specificity. Recombinant CAMKV‐specific assays (cell‐based [fixed and live] and Western blot) provided additional confirmation.ResultsOf 5 CAMKV‐IgG positive patients, 3 were women (median symptom‐onset age was 59 years; range, 53–74). Encephalitis‐onset was subacute (4) or acute (1) and manifested with: altered mental status (all), seizures (4), hyperkinetic movements (4), psychiatric features (3), memory loss (2), and insomnia (2). Paraclinical testing revealed CSF lymphocytic pleocytosis (all 4 tested), electrographic seizures (3 of 4 tested), and striking MRI abnormalities in all (mesial temporal lobe T2 hyperintensities [all patients], caudate head T2 hyperintensities [3], and cortical diffusion weighted hyperintensities [2]). None had post‐gadolinium enhancement. Cancers were uterine adenocarcinoma (3 patients: poorly differentiated or neuroendocrine‐differentiated in 2, both demonstrated CAMKV immunoreactivity), bladder urothelial carcinoma (1), and non‐Hodgkin lymphoma (1). Two patients developed encephalitis following immune checkpoint inhibitor cancer therapy (atezolizumab [1], pembrolizumab [1]). All treated patients (4) demonstrated an initial response to immunotherapy (corticosteroids [4], IVIG [2]), though 3 died from cancer.InterpretationCAMKV‐IgG is a biomarker of immunotherapy‐responsive paraneoplastic encephalitis with temporal and extratemporal features and uterine cancer as a prominent oncologic association. ANN NEUROL 2024;96:21–33
Biocompatible Cable Ties Are an Alternative to Metal Stabilizers for Bar Securement During Minimally Invasive Pectus Excavatum Repair
Raikot, Swathi R. , Polites, Stephanie F. , Potter, D. Dean

Journal of Laparoendoscopic & Advanced Surgical Techniques | April 18, 2024 | Volume: 34 | Issue: 10 | Pages: 936-940

10.1089/lap.2023.0417 | PMID 38634817 Get It

Background: Bar stabilization during minimally invasive pectus excavatum repair (MIRPE) is critical to avoid dislodgement. Multiple techniques are described including stabilizers, wires, and sutures. This retrospective study compared bar movement and outcomes between existing techniques and ZipFix™, a biocompatible cable tie. Methods: Patients ≤20 years of age who underwent MIRPE with ZipFix between January 2021 and September 2022 were compared with historical controls who underwent repair by same surgeons between January 2018 and December 2020 using stabilizers or polydioxanone suture (PDS). Demographics, clinical details, and outcomes were compared using Kruskal–Wallis and chi-square tests. Results: Of the 116 patients who underwent repair, 45 had bars secured with ZipFix (39%) and 71 (61%) were historical controls (35 stabilizer, 36 PDS). Median (interquartile range) age was 15 (14–16) years and Haller index was 3.9 (3.6–4.5). Nine (8%) patients required two bars. Haller index and use of second bar were comparable between stabilization techniques ( P > .05). In total, 49 patients (40%) reported any pain at 1 month and this was similar between stabilization techniques ( P = .45). Median bar movement was greater for bars secured with PDS than with ZipFix or stabilizers at 1 month (5.5 versus 2.3 versus 3.3°, P = .010) and last follow-up (6.5 versus 2.1 versus 3.6°, P < .001). One patient whose bar was secured with PDS required revision for dislodgement. Conclusion: Pectus bar stabilization with ZipFix is a safe alternative to metal stabilizers and both techniques are superior to suture stabilization alone. The use of ZipFix may be preferred given its lower cost and ease of use.